Stevanato Group (STVN) 주식 개요
스테바나토 그룹은 유럽, 중동, 아프리카, 북미, 남미, 아시아 태평양 지역의 바이오 제약 및 헬스케어 산업을 위한 솔루션을 제공하기 위해 제품 및 공정의 설계, 생산, 유통에 관여하고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 STVN에 대한 위험이 감지되지 않았습니다.
STVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stevanato Group S.p.A. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$17.85 |
| 52주 최고가 | US$28.00 |
| 52주 최저가 | US$12.89 |
| 베타 | 0.75 |
| 1개월 변동 | 16.29% |
| 3개월 변동 | 11.22% |
| 1년 변동 | -21.05% |
| 3년 변동 | -33.27% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -9.25% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • May 08
STVN: Core Biologics Shift Will Support Future Earnings Power Despite Guidance Reset
Narrative Update Analysts have trimmed Stevanato Group's average price target to reflect the recent cuts to $19, $26, $28 and $32, with updated models indicating a fair value estimate of about $24.81. This is based on slightly lower margin assumptions, a modest adjustment to long term growth, a somewhat lower discount rate, and a higher expected future P/E multiple.내러티브 업데이트 • Apr 23
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.
내러티브 업데이트 • Apr 09
STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.
내러티브 업데이트 • Mar 26
STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.내러티브 업데이트 • Mar 11
STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.내러티브 업데이트 • Feb 25
STVN: Large-Volume Self-Administration Partnership Will Support Future Upside Potential
Analysts have trimmed their 12 month price target on Stevanato Group by about $4.90 per share to reflect updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E multiples, citing recent Street research calls that include Jefferies cutting its target by $5.50. Analyst Commentary Bearish analysts are signaling a more cautious stance on Stevanato Group, reflected in reduced 12 month price targets that factor in updated views on fair value, discount rates, revenue growth, profit margins, and future P/E multiples.내러티브 업데이트 • Feb 09
STVN: Large Volume On-Body Delivery Partnership Will Support Stronger Future Cash Flows
Analysts have nudged their fair value estimate for Stevanato Group slightly higher to US$36.09, citing small adjustments to discount rate assumptions, revenue growth outlook, profit margin expectations, and a refined future P/E framework. What's in the News Datwyler, LTS Device Technologies and Stevanato Group entered a collaboration focused on large volume subcutaneous drug delivery using on-body administration for larger dose volumes (Key Developments).분석 기사 • Feb 04
Why We're Not Concerned Yet About Stevanato Group S.p.A.'s (NYSE:STVN) 27% Share Price Plunge
Unfortunately for some shareholders, the Stevanato Group S.p.A. ( NYSE:STVN ) share price has dived 27% in the last...내러티브 업데이트 • Jan 26
STVN: Large Volume Drug Delivery Collaboration Will Support Stronger Future Cash Flows
Analysts have nudged their price target for Stevanato Group slightly higher to $36.08 from $36.05, citing updated assumptions for revenue growth, profit margins, and future P/E that modestly adjust their long term valuation. What's in the News Datwyler, LTS Device Technologies and Stevanato Group announced a collaboration focused on large volume subcutaneous drug delivery, targeting more convenient on body administration of larger doses for patients, with a joint platform to be presented at Pharmapack in Paris on January 21 to 22, 2026 (Key Developments).내러티브 업데이트 • Jan 11
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts now estimate Stevanato Group's fair value price target at approximately US$36.05, a very small adjustment from about US$36.08. This reflects updated views that combine slightly higher revenue growth expectations with modestly lower profit margin assumptions and a marginally higher future P/E outlook.분석 기사 • Jan 06
Are Stevanato Group S.p.A. (NYSE:STVN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stevanato Group fair value estimate is US$16.36 Current share...Seeking Alpha • Jan 03
Stevanato: Structural Growth Intact, Buy Confirmed
Summary Stevanato's biologics remain the core growth engine supported by a broad pipeline, resilient GLP-1 demand, vial recovery, and a favorable industry backdrop. While Engineering continues to weigh on margins in the short run, the weakness appears cyclical rather than structural, with optimization progressing and limited impact on group fundamentals. After a ~14% pullback, long-term earnings visibility remains strong, supporting higher 2026 profitability assumptions and a higher target price, leading us to maintain a constructive stance. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 27
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts have nudged their price target on Stevanato Group slightly higher to approximately $36.08 per share from about $36.05, citing modestly stronger expectations for revenue growth and profit margins that more than offset a small anticipated decline in the company’s future price to earnings multiple. What's in the News Maintained 2025 revenue guidance, expecting between €1.160 billion and €1.190 billion, signaling confidence in demand and operational execution (Corporate Guidance) Announced a significant expansion of drug delivery system manufacturing capacity in Bad Oeynhausen, Germany, adding over 2,500 square meters of advanced production space to support global pharma and biotech customers (Business Expansions) Invested multi millions in an ISO 8 cleanroom environment equipped for injection molding and automated assembly, aimed at strengthening resilient, Europe based supply chains for partners (Business Expansions) Enhanced the Bad Oeynhausen site to scale production of key devices such as the Aidaptus autoinjector and Alina pen injector platforms, reinforcing the company’s role in patient centric combination products (Business Expansions) Valuation Changes Fair Value Estimate has risen slightly to approximately $36.08 per share from about $36.05.내러티브 업데이트 • Dec 12
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Profit Margins
Analysts have modestly trimmed their price target on Stevanato Group to approximately $36.05 from about $36.07, reflecting slightly higher perceived risk via a raised discount rate, which is only partly offset by improved profit margin expectations and a marginally lower forecast valuation multiple. What's in the News Maintained 2025 revenue guidance, with expected revenue in the range of €1.160 billion to €1.190 billion (Corporate guidance) Announced a significant expansion of drug delivery system manufacturing capacity at its Bad Oeynhausen, Germany facility, adding over 2,500 square meters of advanced production space (Business expansion) Invested multiple millions in a new ISO 8 cleanroom, injection molding, and automated assembly operations to support global pharma and biotech partners with resilient European supply chains (Business expansion) Strengthened production capabilities for key platforms, including the Aidaptus autoinjector and Alina pen injector, enhancing its role in patient centric combination products (Business expansion) Valuation Changes Fair Value Estimate: edged down slightly to approximately €36.05 from about €36.07 per share, reflecting a marginally lower intrinsic valuation.내러티브 업데이트 • Nov 25
STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations. What's in the News Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).내러티브 업데이트 • Nov 11
STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside
Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.분석 기사 • Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Stevanato Group S.p.A.'s ( NYSE:STVN ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong...분석 기사 • Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
NYSE:STVN 1 Year Share Price vs Fair Value Explore Stevanato Group's Fair Values from the Community and select yours A...분석 기사 • Jun 23
Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 09
Stevanato: Ramping Syringe Demand, Buy Confirmed
Summary Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war. Stevanato's valuation is supported by sales accelleration and EBITDA growth evolution. Read the full article on Seeking Alpha
새로운 내러티브 • Nov 20
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Seeking Alpha • Nov 13
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Summary Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target. Read the full article on Seeking AlphaSeeking Alpha • May 29
Stevanato: Destock Pressures, Long-Term Upside
Summary Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand. STVN is not trading at a premium compared to its peers. Therefore, we reinstated a buy rating status. Read the full article on Seeking AlphaSeeking Alpha • Mar 12
Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Summary Stevanato's peers decided to lower sales growth estimates in 2024 due to clients' destocking activities. The company's EBITDA and net profit declined due to start-up costs and an unfavorable exchange rate effect. Stevanato's valuation looks full compared to its peers. We move our rating to neutral. Read the full article on Seeking Alpha주주 수익률
| STVN | US Life Sciences | US 시장 | |
|---|---|---|---|
| 7D | -0.8% | 1.6% | -0.3% |
| 1Y | -21.1% | 7.1% | 26.7% |
수익률 대 산업: STVN은 지난 1년 동안 7.1%의 수익을 기록한 US Life Sciences 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: STVN은 지난 1년 동안 26.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: STVN는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: STVN의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1949 | 6,010 | Franco Stevanato | www.stevanatogroup.com |
스테바나토 그룹은 유럽, 중동, 아프리카, 북미, 남미, 아시아 태평양 지역의 바이오 제약 및 헬스케어 산업을 위한 솔루션을 제공하기 위해 제품 및 공정의 설계, 생산, 유통에 종사하고 있습니다. 이 회사는 바이오제약 및 진단 솔루션과 엔지니어링의 두 부문으로 운영되고 있습니다. 이 회사는 사전 충전형 주사기, 카트리지, 바이알, 앰플로 구성된 약물 봉쇄 솔루션, 체외 진단 솔루션, 펜 주입기, 자동 주입기, 웨어러블 주입기 등 약물 전달 시스템, 진단 실험실 소모품, 분석 및 규제 지원 서비스, 의료 기기, 의약품 육안 검사기, 조립 및 포장 기계, 유리 변환 기계, 라인 최적화 및 라인 전환, 교육, 물류, 예비 부품 및 유지보수 서비스와 같은 판매 후 서비스 등을 제공합니다.
Stevanato Group S.p.A. 기초 지표 요약
| STVN 기초 통계 | |
|---|---|
| 시가총액 | US$4.85b |
| 순이익 (TTM) | US$164.21m |
| 매출 (TTM) | US$1.40b |
29.7x
주가수익비율(P/E)3.5x
주가매출비율(P/S)STVN는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| STVN 손익계산서 (TTM) | |
|---|---|
| 매출 | €1.20b |
| 매출원가 | €851.68m |
| 총이익 | €351.58m |
| 기타 비용 | €210.23m |
| 순이익 | €141.35m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.52 |
| 총이익률 | 29.22% |
| 순이익률 | 11.75% |
| 부채/자본 비율 | 28.3% |
STVN의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.4%
현재 배당 수익률10%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 23:55 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Stevanato Group S.p.A.는 17명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Hugo Solvet | BNP Paribas |
| Curtis Moiles | BNP Paribas |
| Michael Ryskin | BofA Global Research |